Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chemring surges as Bain Capital said to have made takeover proposal

(Sharecast News) - Chemring surged to the top of the FTSE 250 on Monday following a Sky News report that private equity firm Bain Capital has made an approach to buy the defence group. One source suggested to Sky that an initial offer may have been tabled at 390p a share. This is a modest premium to the 356p at which the stock was trading on Monday morning.

They also said that a second offer had been under preparation by Bain, although it was unclear whether it had been submitted to the company's board.

Another insider told Sky there was uncertainty about how aggressively Bain was prepared to pursue the company.

Chemring employs roughly 2,700 people, according to its most recent results announcement published in mid-December.

Shares in Chemring slumped on 17 December, despite the firm reporting a record order book amid global political tensions and the war in Ukraine.

The company said at the time that revenues rose 8% to £510m in the year to 31 October. Underlying core earnings were up 6% to £93.7m and the order book surged 13% to £12.03bn.

However, it also reported operational challenges at its Tennessee countermeasures business due to production being disrupted by adverse weather conditions and delays in the ramp up of its automated facility.

"The underlying operating profit margin was also adversely affected by deliveries made on a legacy contract from 2016 for the supply of countermeasures to the US Department of Defence. Having previously been expected to complete in the second half of the financial year, the customer has now exercised an option to extend the duration of this contract, which will now conclude in the first half of FY25," Chemring said.

At 1215 GMT, the shares were up 13.5% at 406.20p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.